Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor
about
Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finInteraction of histidine-rich glycoprotein with fibrinogen and fibrinCharacterization of cDNA coding for human factor XIIIaCharacterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factorNMR Solution Structure, Stability, and Interaction of the Recombinant Bovine Fibrinogen αC-Domain Fragment †Two non-proline cis peptide bonds may be important for factor XIII functionCrystallization of blood coagulation factor XIII by an automated procedureSecondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrinFactor XIII: novel structural and functional aspects.Minor Role of Plasminogen in Complement Activation on Cell Surfaces.Organization of the human alpha 2-plasmin inhibitor gene"Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin moleculesEnzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension.Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.Congenital alpha(2)-plasmin inhibitor deficiencies: a review.Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.Binding and covalent cross-linking of purified von Willebrand factor to native monomeric collagen.Tissue-type plasminogen activator increases the binding of glu-plasminogen to clotsCase report of an acquired factor XIII inhibitor: diagnosis and management.Functional factor XIII-A is exposed on the stimulated platelet surfaceEvaluating factor XIII specificity for glutamine-containing substrates using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay.Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen.alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorderRapid formation of large molecular weight alpha-polymers in cross-linked fibrin induced by high factor XIII concentrations. Role of platelet factor XIII.Ranking reactive glutamines in the fibrinogen αC region that are targeted by blood coagulant factor XIII.Fission yeast Cyk3p is a transglutaminase-like protein that participates in cytokinesis and cell morphogenesis.Roles of transglutaminases in cardiac and vascular diseases.Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activityIdentification of an ordered compact structure within the recombinant bovine fibrinogen alphaC-domain fragment by NMR.Characteristics of fibrin formation and clot stability in individuals with congenital type IIb protein C deficiencyPopulation pharmacokinetics of recombinant factor XIII in cynomolgus monkeysSynergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.Factor XIII: a coagulation factor with multiple plasmatic and cellular functions.Evidences for a role of protein cross-links in transglutaminase-related disease.Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control.Substrates of Factor XIII-A: roles in thrombosis and wound healing.A gamma methionine-310 to threonine substitution and consequent N-glycosylation at gamma asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi.Biophysical Mechanisms Mediating Fibrin Fiber Lysis.Hemoglobin-based oxygen carriers promote systemic hyperfibrinolysis that is both dependent and independent of plasmin.
P2860
Q24300911-08B128B4-6AA6-416F-A9EC-3FBD7F51F31AQ24563598-C464345A-4544-40E0-B736-BCD5DDC69E47Q24629195-83FE3D3E-5E1C-4111-A6F8-A10287576D6FQ24651881-5614F558-3688-4148-A561-D90EF9F8F2B2Q27646405-D912C602-F747-4D43-A468-AA3FF01C2035Q27748965-7D43A67C-7D19-43BF-965D-BD822259B4FEQ28290244-BEAAF336-A6F8-4822-95F2-09EB2C2E674CQ28366715-91077402-EC6B-48C4-97B9-368D90892A3CQ30156007-597D3405-365E-4F0C-B1E9-9B077774484CQ33428157-E7A81EB5-AE4B-40CA-98D6-428E10DBFF9FQ33648214-CB43911D-8807-4694-A623-2C391940BB37Q33822352-6207FBE1-592F-4E2D-9EFB-5FF1A53399BEQ33896814-913AF6F7-FA5F-46B9-B36F-E2FF17301694Q34101596-B3DE12AE-80E0-4160-BC2F-E5E2F72F9123Q34319340-68085EDD-689F-4E61-8AAE-275D2A19F227Q34529594-8F54A596-212C-40DD-A6B1-1193D60352B1Q34534629-9327C3D9-58E9-42FE-B0DF-4503941B5810Q34621741-D49F4D86-65C0-4CF9-AB2F-4FBA13620BD7Q34703713-DE5D5CA3-BEF1-4E52-B8FC-D51E3262EE25Q35023065-FFE94A1D-14C2-4C5E-AF07-35D536DD6628Q35153828-6BACC7A5-9A40-4A23-AC72-D0FF37896744Q35206931-51781196-B6C3-4A37-9D3C-4F0DD27C40A6Q35581846-0868FF85-10A5-4A10-8A47-3D7900C04121Q35582088-DC3C5689-7D2A-4183-BF1A-257C7F074684Q35948493-EB3A2522-4506-4679-A0FA-26CE37C88231Q36066623-36865C45-9308-4913-A2D3-2AE0BD7B0510Q36664166-62D7CA4D-A9DA-46FE-8B7F-618A15838D28Q36993272-AB640B36-47C0-4328-A099-DD65EB3884D9Q37003131-E54F6FC0-E13A-40F7-AD21-D15A5385FE09Q37059445-5BB2F522-8850-40E9-82BB-28D45590FAD3Q37361764-B94C0DFC-B812-4378-A2D1-6FC6CA5D75D0Q37687654-0301C00D-7EDE-41C4-B7E4-98754A6F1226Q37692590-D4BBCDA3-8117-4421-8772-91823F61C317Q37899674-FC2181C9-AD32-4F34-93C0-2F8E00E676A0Q37907975-2A2BE9F5-582A-4684-8027-3952883C4838Q38000164-F1594622-7539-4476-8E7F-630777141F88Q38052936-E7AE6655-C5CF-4E3B-A44D-118481A25AF8Q38344795-B007C678-D0EB-4207-9061-C0B374328DE6Q38669149-47B474E6-AD57-4F13-8693-0FE5125727CEQ38732501-758B12DF-83A5-4354-8D0B-22017A5A83DA
P2860
Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 1980
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor
@en
Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
@nl
type
label
Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor
@en
Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
@nl
prefLabel
Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor
@en
Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
@nl
P2860
P356
P1476
Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor
@en
P2860
P304
P356
10.1172/JCI109671
P407
P577
1980-02-01T00:00:00Z